Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) Cost of Revenue (2020 - 2025)

Historic Cost of Revenue for Silence Therapeutics (SLN) over the last 6 years, with Q3 2025 value amounting to $64000.0.

  • Silence Therapeutics' Cost of Revenue fell 9824.13% to $64000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year decrease of 8041.53%. This contributed to the annual value of $11.8 million for FY2024, which is 821.48% down from last year.
  • Latest data reveals that Silence Therapeutics reported Cost of Revenue of $64000.0 as of Q3 2025, which was down 9824.13% from $85000.0 recorded in Q2 2025.
  • In the past 5 years, Silence Therapeutics' Cost of Revenue registered a high of $5.5 million during Q1 2023, and its lowest value of $2119.4 during Q1 2021.
  • For the 5-year period, Silence Therapeutics' Cost of Revenue averaged around $2.4 million, with its median value being $2.8 million (2024).
  • Its Cost of Revenue has fluctuated over the past 5 years, first surged by 14393483.68% in 2022, then tumbled by 9824.13% in 2025.
  • Silence Therapeutics' Cost of Revenue (Quarter) stood at $2.8 million in 2021, then soared by 64.44% to $4.5 million in 2022, then plummeted by 63.09% to $1.7 million in 2023, then rose by 21.99% to $2.0 million in 2024, then crashed by 96.86% to $64000.0 in 2025.
  • Its Cost of Revenue was $64000.0 in Q3 2025, compared to $85000.0 in Q2 2025 and $54000.0 in Q1 2025.